Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) General Information

Description

Worldwide rights, except China, Hong Kong, Taiwan and Macau, to RHB-107, a serine protease inhibitor that works against a range of human trypsins, of a pharmaceutical company based in Ladenburg, Germany.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Schriesheimer Straße 101
  • 68526 Ladenburg
  • Germany
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Pharmaceuticals
Corporate Office
  • Schriesheimer Straße 101
  • 68526 Ladenburg
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau)‘s full profile, request access.

Request a free trial

Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau)‘s full profile, request access.

Request a free trial

Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) FAQs

  • Where is Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) headquartered?

    Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) is headquartered in Ladenburg, Germany.

  • What industry is Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) in?

    Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau)’s primary industry is Buildings and Property.

  • Is Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) a private or public company?

    Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) is a Private company.

  • What is Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau)’s current revenue?

    The current revenue for Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) is .

  • Who are Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau)’s investors?

    Heidelberg Pharma has invested in Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau).

  • Who acquired Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau)?

    Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) was acquired by RedHill Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process